[Form 4] Beta Bionics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Stephen Feider, identified as an officer (Chief Financial Officer) of Beta Bionics, Inc. (BBNX), reported a sale of common stock on 09/02/2025. The Form 4 shows 1,462 shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units. The weighted average sale price was $18.8632, with prices ranging from $18.58 to $19.09. After the transaction, Mr. Feider beneficially owned 44,041 shares (reported as direct ownership). The filing is signed by Stephen Feider on 09/03/2025. No derivative transactions or other changes are reported.

Insights

Financial Analyst

TL;DR: Routine tax-withholding sale of vested RSUs by the CFO; small share disposition relative to total holdings, not a material corporate event.

The transaction is reported as a sale to satisfy tax withholding on vested restricted stock units, a common administrative action that does not indicate change in corporate outlook or insider confidence. The sold amount (1,462 shares at a weighted average of $18.8632) reduced direct holdings to 44,041 shares. There are no reported option exercises, grants, or derivative changes accompanying this Form 4, and no statements of intent that would suggest strategic repositioning.

Corporate Governance Expert

TL;DR: Compliance filing shows standard insider reporting and tax-withholding sale; disclosure appears complete and properly signed.

The Form 4 discloses the relationship of the reporting person as an officer (Chief Financial Officer) and includes the required explanation that the sale covered tax withholding for vested RSUs. The weighted average sale price and price range are provided, and the form is signed and dated. From a governance and disclosure perspective, the filing meets routine Section 16 reporting expectations and contains the explanatory note required for such transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feider Stephen

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		S(1)		1,462	D	$18.8632(2)	44,041	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

2. The weighted average sale price for the transaction reported was $18.8632 and the range of prices were between $18.58 and $19.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Stephen Feider	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Beta Bionics (BBNX) insider Stephen Feider report on Form 4?

The Form 4 reports that Stephen Feider, the company's Chief Financial Officer, sold 1,462 shares of common stock on 09/02/2025 to cover tax withholding for vested restricted stock units.

At what price were the shares sold according to the Form 4 for BBNX?

The weighted average sale price was reported as $18.8632, with the sale prices ranging between $18.58 and $19.09.

How many BBNX shares does Stephen Feider own after the reported transaction?

After the reported sale, Mr. Feider beneficially owned 44,041 shares, reported as direct ownership.

Why were the shares sold in the reported Form 4?

The filing explains the shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

When was the Form 4 signed and filed for the BBNX transaction?

The Form 4 is signed by Stephen Feider and dated 09/03/2025.